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Type I interferon responses in rhesus macaques
prevent SIV infection and slow disease progression
Netanya G. Sandler1{, Steven E. Bosinger2,3, Jacob D. Estes4, Richard T. R. Zhu1, Gregory K. Tharp2,3, Eli Boritz1, Doron Levin5,
Sathi Wijeyesinghe1, Krystelle Nganou Makamdop1, Gregory Q. del Prete4, Brenna J. Hill1, J. Katherina Timmer1, Emma Reiss1,
Ganit Yarden5, Samuel Darko1, Eduardo Contijoch1, John Paul Todd6, Guido Silvestri2, Martha Nason7, Robert B. Norgren Jr8,
Brandon F. Keele4, Srinivas Rao6, Jerome A. Langer9, Jeffrey D. Lifson4, Gideon Schreiber5 & Daniel C. Douek1

Inflammation in HIV infection is predictive of non-AIDS morbidity
and death1, higher set point plasma virus load2 and virus acquisition3;
thus, therapeutic agents are in development to reduce its causes and
consequences. However, inflammation may simultaneously confer
both detrimental and beneficial effects. This dichotomy is particularly
applicable to type I interferons (IFN-I) which, while contributing to
innate control of infection4–10, also provide target cells for the virus
during acute infection, impair CD4 T-cell recovery, and are associated
with disease progression6,7,11–19. Here we manipulated IFN-I signalling
in rhesus macaques (Macaca mulatta) during simian immunodeficiency virus (SIV) transmission and acute infection with two complementary in vivo interventions. We show that blockade of the IFN-I
receptor caused reduced antiviral gene expression, increased SIV reservoir size and accelerated CD4 T-cell depletion with progression to
AIDS despite decreased T-cell activation. In contrast, IFN-a2a administration initially upregulated expression of antiviral genes and prevented systemic infection. However, continued IFN-a2a treatment
induced IFN-I desensitization and decreased antiviral gene expression,
enabling infection with increased SIV reservoir size and accelerated
CD4 T-cell loss. Thus, the timing of IFN-induced innate responses in
acute SIV infection profoundly affects overall disease course and outweighs the detrimental consequences of increased immune activation.
Yet, the clinical consequences of manipulation of IFN signalling are
difficult to predict in vivo and therapeutic interventions in human
studies should be approached with caution.
We designed and produced an IFN-I receptor antagonist (IFN-1ant)
that blocks IFN-a2 antiviral and antiproliferative activity in vitro19. Six
rhesus macaques received 1 mg of IFN-1ant daily for 4 weeks following intrarectal challenge with SIVMAC251 (dosage based on previous dose–
response studies; Extended Data Fig. 1a–d); nine macaques received
saline (Extended Data Fig. 1e). Initial assessment of in vivo effects revealed
delayed peak mRNA expression of MX1 and OAS2 in the IFN-1ant macaques (Extended Data Fig. 2a, b), but peak expression levels did not differ
between cohorts. Whole-transcriptome sequencing revealed that expression of most interferon-stimulated genes (ISGs) in peripheral blood mononuclear cells (PBMCs) was significantly decreased at 7 days post-infection
(d.p.i.) in the IFN-1ant-treated compared to placebo-treated macaques
(Fig. 1a), including the antiviral genes APOBEC3G and MX2, those that
code for cyclic GMP-AMP synthase (cGAS) and tetherin4,5,20, and IRF7,
a master IFN-I signalling inducer21, indicating profound disruption of
IFN-I signalling (Fig. 1b). Most ISGs in the IFN-1ant group normalized
at 10 and 21 d.p.i. and were upregulated at 28 and 84 d.p.i. (Extended Data
Fig. 2c). Consistent with transcriptional data (Extended Data Fig. 2d, e),

APOBEC3G, TRIM5a and MX2 protein expression by quantitative immunohistochemistry was significantly attenuated in lymph nodes at 4 weeks
post-infection (w.p.i.) compared to placebo (Fig. 1c). Thus, IFN-1ant
treatment during acute SIV infection resulted in delayed and decreased
antiviral gene and protein expression in peripheral blood and lymph nodes.
Consistent with reduced antiviral gene expression, IFN-1ant macaques
had significantly higher plasma viral loads (pVLs) than placebo macaques
during acute infection (Fig. 2a) and after 20 w.p.i. despite similar numbers
of transmitted/founder viruses (measured 10 d.p.i., Extended Data Fig. 8a).
Delayed peak ISG expression, however, was predictive of higher pVLs at
peak and 12 w.p.i. and higher PBMC-associated SIV gag DNA levels at
28 d.p.i. (Extended Data Fig. 2f–h). Additionally, the number of lymph node
SIV RNA1 cells per mm2 as determined by in situ hybridization was significantly higher in macaques treated with IFN-1ant compared to placebo
during chronic infection (Fig. 2b). Thus, early IFN-I signalling was critical
for early and long-term control of SIV replication and virus reservoir size.
Although both groups experienced a similar, significant decrease in
circulating CD4 T-cell frequency (Fig. 2c) and CD4/CD8 T-cell ratio
(Extended Data Fig. 3a) between 0 and 12 w.p.i., IFN-1ant macaques experienced a profound decline with a lower lymph node CD4 T-cell frequency
and CD4/CD8 T-cell ratio beyond 12 w.p.i. (Fig. 2d and Extended Data
Fig. 3b). The frequency of CCR51 memory CD4 T cells, potential targets
for infection, was significantly lower in blood in IFN-1ant-treated than
placebo-treated rhesus macaques through 12 w.p.i. (Fig. 2e), and lymph
nodes at 4 and .12 w.p.i. (Fig. 2f), suggesting depletion due to infection.
Circulating T-cell activation, reflected by HLA-DR1 and Ki671 memory
CD4 and CD8 T-cell frequencies, was not significantly different between
groups at 4 or .12 w.p.i. (Supplementary Information). However, HLADR1 and Ki671 memory CD4 and CD8 T-cell frequencies were significantly lower in the lymph nodes of IFN-1ant macaques than placebo at
.12 w.p.i. (Extended Data Fig. 3c–f). Taken together, IFN-I signalling
blockade during acute SIV infection resulted in attenuated T-cell activation in lymphoid tissue yet accelerated CD4 T-cell depletion.
Clinical outcome ultimately gives the most comprehensive measure
of disease state. Consistent with a median life expectancy of 1 year22, the six
placebo-treated macaques followed through 44 w.p.i. (three were transferred to another study before 30 w.p.i.) lived, but the IFN-1ant macaques
began dying of AIDS at 24 w.p.i. and all were euthanized per protocol for
signs of AIDS by 30 w.p.i. (Fig. 2g). Thus, blocking IFN-I signalling during
only the first 4 weeks of infection resulted in accelerated disease progression and death from AIDS.
Exploration of the molecular mechanisms underlying the accelerated
disease progression by whole-transcriptome sequencing revealed statistically
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Figure 1 | IFN-1ant suppresses early antiviral responses. a, Expression of
ISGs in macaques treated with IFN-1ant (n 5 6) or placebo saline (n 5 9)
7 days after SIV infection. FPKM (log-transformed fragments per kilobase of
transcript per million fragments sequenced) reflects the relative abundance of
transcripts. P values indicate differentially expressed genes at 7 d.p.i.
b, Expression assessed by RNA sequencing (RNA-seq) of antiviral genes
APOBEC3G, MX2 and those that code for cGAS and tetherin in PBMCs before
and 7 days after SIV infection in macaques that received IFN-1ant (Ant, n 5 6)
or placebo (Plac, n 5 9) injections. Error bars indicate range. P values were
calculated by Mann–Whitney U test. c, APOBEC3G, TRIM5a and MX2

protein expression by immunohistochemistry of lymph nodes (LNs) at 4 w.p.i.
in placebo (n 5 6) and IFN-1ant (n 5 6) macaques. Horizontal bars represent
median values. P values were calculated by Mann–Whitney U test. The left
panels are representative images of APOBEC3G staining from each group.
d, Expression of genes involved in pattern recognition receptor signalling of
IFN-1ant-treated (n 5 6) macaques compared to placebo (n 5 9). P values
represent the differential expression between IFN-1ant and placebo macaques
at 7 d.p.i. For all panels, IFN-1ant-treated macaques are represented in red,
placebo-treated macaques in blue.

significant enrichment of pathways regulating innate immunity, IFNI production and T- and B-lymphocyte activation (Extended Data Fig.
4a–c) with significant downregulation of most genes in the IFN-1ant
group at 7 d.p.i. compared to placebo-treated controls (Fig. 1d and Extended
Data Fig. 2c). Relative to placebo, the most significantly perturbed pathway in the IFN-1ant-treated animals consisted of pathogen-associated
pattern recognition receptor (PRR) signalling molecules (Fig. 1d and
Extended Data Fig. 4a), with significant downregulation of several viral
PRRs (TLR3, TLR7, DDX58/RIG-I, MDA5/IFIH1) and their downstream
adaptors (TICAM1/TRIF) or transcription factors (IRF7) in IFN-1ant
macaques compared to placebo (Extended Data Fig. 4c). Concordantly,
expression of the downstream mediators IL-6, TNF and IL-1b was significantly reduced.
Consistent with their responsiveness to IFN-I23, the frequencies of total
and cytotoxic CD161 natural killer (NK) cells were significantly lower in
the IFN-1ant group than placebo at .12 w.p.i., although there were no diferences at 4 w.p.i. (Extended Data Fig. 3g–i). However, we observed no significant differences in phenotype, function or timing of CD4 or CD8 T-cell
responses (Extended Data Fig. 5 and Supplementary Information).
Collectively, these data suggest that IFN-I signalling early in SIV infection is critical for innate immune control of virus replication and that its
antagonism, even if only brief during the acute phase, results in decreased
virus control, accelerated CD4 T-cell depletion and progression to AIDS.
Given these findings, we hypothesized that administering IFN-I could
improve SIVMAC251 control despite evidence suggesting that inflammation
exacerbates virus acquisition and disease progression1–3,13. Six macaques
received 6 mg kg21 pegylated IFN-a2a dosed weekly, as determined in
prior studies24, starting 1 week before challenge and continued through
4 weeks after systemic infection (defined as detectable pVL 7 days postchallenge). Macaques were followed until 12 w.p.i. then euthanized per
protocol (Extended Data Fig. 1e). Whereas all nine placebo macaques were
infected after the first intrarectal inoculation, IFN-a2a treatment significantly delayed systemic infection, necessitating two, three or five challenges
to infect these macaques (Fig. 3a), and significantly decreased the number
of transmitted/founder variants (Extended Data Fig. 8a). The macaques
that required more challenges had fewer transmitted/founder variants
(Fig. 3b); however, the circulating viruses at peak viral load in both groups

were equally susceptible to in vitro IFNa inhibition (data not shown).
Thus, treatment with IFN-a2a during SIV challenge increased host resistance to systemic infection.
We assessed whether ISGs may have contributed to resistance to infection. We found that MX1 and OAS2 gene expression detected by quantitative reverse transcription PCR (qRT–PCR) increased after one IFN-a2a
dose but decreased after repeated administration, suggesting an IFNdesensitized state (Extended Data Fig. 6a–d) resulting in no significant
differences between treated and placebo groups on the day of infectious
challenge. Furthermore, IFN-a2a macaques had lower ISG expression
compared to placebo at 7 and 10 d.p.i., including those encoding cGAS,
APOBEC3G, MX2 and tetherin (Fig. 3c–f and Extended Data Fig. 7a–b).
At 4 w.p.i., after 6, 7 or 9 doses of IFN-a2a, lymph node TRIM5a protein
expression was significantly lower in the IFN-a2a group compared to
placebo (Extended Data Fig. 8b). To explore the effects of IFN-a2a administration on ISG expression further, we performed whole-transcriptome
sequencing on uninfected rhesus macaques administered pegylated IFNa2a for 3 weeks. Seven days after one IFN-a2a dose, expression of virus
restriction factors including TRIM22, MX2 and IRF7 was increased in
PBMCs, lymph nodes and rectum (Extended Data Fig. 7c–h). However,
after 3 doses these ISGs returned to pre-treatment expression levels (MX2)
or lower (TRIM22 and IRF7), consistent with the timing of infection of the
SIV-challenged macaques. (Extended Data Fig. 7c–h). We found no in
vitro IFN-neutralizing activity in the plasma at the time of infection to
explain the loss of exogenous IFN-a2a activity (Extended Data Fig. 6e
and Supplementary Information), suggesting that ISG downregulation
probably occurred as a result of intrinsic regulatory mechanisms. Indeed,
FOXO3a, a central regulator of IFN-I feedback25, was significantly upregulated in the IFN-a2a compared to placebo macaques at 7 d.p.i. (Fig. 3g
and Extended Data Fig. 6g) and, concordantly, ISGs demonstrated to be
repressibly bound by FOXO3a (ref. 25) had lower expression at 7 d.p.i.
(Extended Data Fig. 6h). We also assessed a broad panel of genes predicted
to be bound by FOXO3a (ref. 25) using gene-set enrichment analysis and
observed a significantly lower cumulative ranking of FOXO3a targets in
the 7 d.p.i. IFN-a2a-treated macaque transcriptome data when contrasted
to the 7 d.p.i. placebo data (Fig. 3h), suggesting increased FOXO3amediated repression in the IFN-a2a macaques. Indeed, after 21 days of
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Figure 2 | IFN-1ant accelerates disease progression in SIV-infected rhesus
macaques. a, Plasma SIV RNA levels during acute and chronic SIV infection in
macaques treated with IFN-1ant (n 5 6) or placebo saline (n 5 9). *P , 0.05.
Shading indicates treatment period. P value represents the comparison between
groups of the areas under the curve (AUC) (0–4 w.p.i.). b, SIV RNA-containing
cells in the lymph nodes by in situ hybridization at 4 and 12 w.p.i. in IFN-1ant
(Ant, n 5 6) and placebo (Plac, n 5 6) macaques. Horizontal bars represent
median values. P value was calculated by Mann–Whitney U test. c, Frequency of
CD4 T cells in peripheral blood during acute and chronic SIV infection in
macaques treated with IFN-1ant (n 5 6) or placebo saline (n 5 9). Error bars
indicate range. Red vertical line indicates day 0 of systemic SIV infection. Shading
indicates treatment period. P value represents the comparison between groups of
the AUC (12-32 w.p.i.). d, Frequency of CD4 T cells in lymph nodes before SIV
infection and at 4 or .12 w.p.i. for IFN-1ant (Ant, n 5 6) and placebo (Plac,
n 5 9) macaques. Horizontal bars represent median values. P values at different
time points within treatment groups were calculated by Wilcoxon matched pairs
signed rank test and between groups by Mann–Whitney U test. e, Frequency of
CCR51 memory (CD281CD951 or CD282CD951/2) CD4 T cells in peripheral
blood in macaques treated with IFN-1ant (n 5 6) or placebo saline (n 5 9). Error
bars indicate range. Red vertical line indicates day 0 of systemic SIV infection.
Shading indicates treatment period. P values represent the comparison between
groups of the AUC (0–12 w.p.i. and 4–12 w.p.i.). f, Frequency of CCR51 memory
CD4 T cells in lymph nodes in macaques treated with IFN-1ant (n 5 6) or placebo
saline (n 5 9). Horizontal bars represent median values. P values at different time
points within treatment groups were calculated by Wilcoxon matched pairs
signed rank test and between groups by Mann–Whitney U test. g, Kaplan–Meier
survival curve comparing macaques treated with IFN-1ant (n 5 6) to macaques
that received placebo (n 5 9). P value indicates the significance by logrank
(Mantel–Cox) test for survival by 32 w.p.i. For all panels, IFN-1ant-treated
macaques are represented in red, placebo-treated macaques in blue.
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Figure 3 | IFN-a2a treatment transiently prevents systemic infection but
results in an IFN-tolerant state. a, Kaplan–Meier survival curve comparing
the number of SIVMAC251 rectal challenges required to achieve systemic
infection in macaques treated with IFN-a2a (n 5 6) or placebo saline (n 5 9).
P value indicates the significance by logrank (Mantel–Cox) test of the number of
challenges required for systemic infection, between 1 and 5 challenges.
b, Correlation between the number of challenges needed to achieve systemic
infection and the number of transmitted/founder (T/F) variants in IFN-a2a
(green, n 5 6), IFN-1ant (red, n 5 6) and placebo (blue, n 5 9) macaques.
P value indicates the significance of the correlation between the number of
challenges and the number of T/F variants in all groups. r indicates the
Spearman’s rank correlation coefficient. c–f, Expression of antiviral mediators in
PBMCs in IFN-a2a-treated (IFN, n 5 6) macaques compared to placebo (Plac,
n 5 9) at 10 d.p.i. Error bars indicate range. P values represent the comparison of
FPKMs between IFN-a2a and placebo at 10 d.p.i. by Mann–Whitney U test.
g, Expression profile of FOXO3a, a negative regulator of type I IFN signalling.
P value represents the comparison of FOXO3a FPKM between IFN-a2a (n 5 6)
and placebo (n 5 9) macaques at 7 d.p.i. h, Gene-set enrichment analysis in
IFN-a2a (n 5 6) and placebo (n 5 9) macaques of genes previously
demonstrated to be overexpressed in FOXO32/2 macrophages25. The line plot
indicates the running-sum of the enrichment score; the leading edge is indicated
in magenta. The relative positions of all genes within the ranked data set are
shown in the stick plot below the x axis. P value indicates statistical significance of
the enrichment score, reflecting lower cumulative ranking of FOXO3a targets in
IFN-a2a-treated macaques compared to placebo at 7 d.p.i. For all panels,
IFN-a2a-treated macaques are represented in green, placebo-treated macaques
in blue.

Given their roles in virus control, T and NK cells were evaluated. No
changes in SIV-specific CD4 or CD8 T-cell responses developed with
repeated challenges, suggesting that resistance to infection did not depend
on adequate T-cell responses (Supplementary Information). However,
higher circulating CD561 NK-cell frequencies after starting IFN-a2a predicted more challenges necessary for infection and were associated with
resistance to infection (Extended Data Fig. 8c). Once the CD561 NK-cell
3 1 J U LY 2 0 1 4 | V O L 5 1 1 | N AT U R E | 6 0 3

©2014 Macmillan Publishers Limited. All rights reserved

RESEARCH LETTER
b
8 × 104
6 × 104
4 × 104

d

P = 5 × 10–5

P = 0.0102
TLR3

4
2

2 × 104
0
<LLQ
Plac IFN Plac IFN Plac IFN

c

14 d.p.i. 28 d.p.i.

RIG-I

300

100

200

50

100

TLR7

P = 0.0003
IFI16

60
40
20

400
300
200
100

P = 0.0118

OAS2

8
6
4
2

P = 0.0007

RNASEL

0
0

2 4
6
8 10 12
Weeks post-infection

0

7 14 21 28 84
Days post-infection

e
P = 0.02

4
3
2
1
0

0 2 4 6 8 10 12
Weeks post-infection

40
30

P = 0.02
P = 0.04

20
10
0

0 2 4 6 8 10 12
Weeks post-infection

f

80

FPKM

CD4 T cells (%)

100

150
FPKM

10 d.p.i.

P = 0.0027

10
8
6
4
2

CCR5+ CD4
memory T cells (%)

6

CD4/CD8 T-cell ratio

P = 0.002

0

7 14 21 28 84
Days post-infection

LN CCR5+
CD4 memory T cells (%)

1 × 105 P = 0.04 P = 0.04

FPKM

SIV gag per 105 cells

a

20

P = 0.02
P = 0.03

15
10
5
0

Plac IFN Plac IFN Plac IFN
Pre-infection 4 w.p.i. ≥12 w.p.i.

Figure 4 | IFN-a2a accelerates disease progression. a, PBMC-associated SIV
gag DNA at 10, 14 and 28 d.p.i. in IFN-a2a macaques (IFN, n 5 6) and placebo
(Plac, n 5 6) macaques. LLQ indicates lower limit of quantification. Horizontal
bars represent median values. P values were calculated by Mann–Whitney
U test. b, Expression of differentially expressed genes involved in pattern
recognition receptor signalling. P values represent the comparison between
FPKMs of IFN-a2a (n 5 6) and placebo (n 5 9) macaques at 7 d.p.i.
c, Frequency of CD4 T cells in peripheral blood during acute and early SIV
infection in IFN-a2a (n 5 6) and placebo (n 5 9) macaques. Error bars
indicate range. Shading indicates treatment period. Red vertical line indicates
day 0 of systemic SIV infection. d, CD4/CD8 T-cell ratio in peripheral blood
during acute and early SIV infection in IFN-a2a (n 5 6) and placebo (n 5 9)

macaques. Error bars indicate range. Shading indicates treatment period. Red
vertical line indicates day 0 of systemic SIV infection. P value represents the
comparison between groups of the AUC (0-12 w.p.i.). e, Frequency of CCR51
memory CD4 T cells in peripheral blood in IFN-a2a (n 5 6) and placebo
(n 5 9) macaques. Error bars indicate range. Shading indicates treatment
period. Red vertical line indicates day 0 of systemic SIV infection. P values
represent the comparison between groups of the AUC (0-4 and 0-12 w.p.i.).
f, Frequency of CCR51 memory CD4 T cells in lymph nodes in IFN-a2a
(n 5 6) and placebo (n 5 9) macaques. Horizontal bars represent median
values. P values were calculated by Mann–Whitney U test. For all panels,
IFN-a2a-treated macaques are represented in green, placebo-treated macaques
in blue.

frequency declined, the macaques became infected. In rectal biopsies at
28 d.p.i., more resistant macaques had higher CD161 NK-cell frequencies
(Extended Data Fig. 8d). Together, these data suggest that IFN-a2a-induced
innate immunity, rather than T-cell responses, protected against SIV infection.
Despite fewer transmitted/founder variants, pVLs did not differ significantly between IFN-a2a and placebo groups (Extended Data Fig. 8e),
potentially obscured by the variability and small number of macaques. PBMCassociated SIV gag DNA levels, however, were significantly higher in the
IFN-a2a group than placebo at 10, 14 and 28 d.p.i. (Fig. 4a). While the
circulating CD4 T-cell frequency (Fig. 4c) and CD4/CD8 T-cell ratio
(Fig. 4d) declined between 0 and 4 w.p.i. in both groups, the CD4/CD8
T-cell ratio was significantly lower in the IFN-a2a group (based on area
under the curve (AUC) (0–12 w.p.i.)). The CCR51 memory CD4 T-cell
frequency in blood was significantly lower in IFN-a2a than placebo
macaques during acute (AUC(0–4 w.p.i.), Fig. 4e) and chronic infection (AUC(0–12 w.p.i.)) and in lymph nodes at 4 (Fig. 4f) and 12 w.p.i.,
although the frequency of CD4 T cells and CD4/CD8 T-cell ratio in lymph
nodes and jejunum were similar between groups at 4 and $12 w.p.i.
(data not shown). Thus, SIV-infected IFN-a2a-treated macaques had
increased CD4 T-cell-associated virus load and greater CD4 T-cell loss
with preferential depletion of the CCR51 subset.
We assessed whether increased immune activation was associated
with this CD4 T-cell loss. The circulating Ki671 memory CD4 and CD8
T-cell frequencies were lower in the IFN-a2a compared to placebo group
during acute infection only (AUC(0–4 w.p.i.)) with no differences in the
frequencies of HLA-DR1 memory T cells (Extended Data Fig. 9a–d). In
the lymph nodes, the frequencies of Ki671 memory CD4 T cells at 4 w.p.i.
and HLA-DR1 memory CD4 T cells at $12 w.p.i. were significantly lower
in the IFN-a2a than placebo group with no differences in CD8 T cells
(Extended Data Fig. 9e–h). Thus, the IFN-a2a macaques had similar
or less immune activation compared to placebo macaques.
We further explored the mechanisms underlying the increased cellassociated SIV and CD4 T-cell depletion in IFN-a2a macaques using
whole-transcriptome sequencing of PBMCs. As with IFN-1ant, IFNa2a administration significantly affected the PRR signalling pathway
(Extended Data Fig. 10a). C1q, TLR3, TLR7 and RIG-I were downregulated in the IFN-a2a macaques, yet expression of IL-6, TNF and IL-1b
was increased at 7 d.p.i. (Fig. 4b and Extended Data Fig. 10b). Mediators

of stress responses and cell survival downstream of IL-6 signalling, such
as MAP2K3, and other anti-apoptotic genes such as DIABLO and BCL2L1
were upregulated at 7 d.p.i. (Extended Data Fig. 10b, 10c), whereas
pro-apoptotic genes including CASP10 were downregulated. Thus, early
IFN-a2a administration increased early expression of proinflammatory
cytokines despite decreased PRR expression and delayed induction of
apoptotic pathways.
We next assessed T- and NK-cell-mediated immunity. IFN-a2a-treated
macaques had intact and even enhanced SIV-specific CD8 T-cell responses
with no deficits in CD4 T-cell responses (Extended Data Fig. 8f–i and
Supplementary Information). Whereas there were no differences at 4 w.p.i.,
between 4 and 12 w.p.i., the CD561 NK-cell frequency increased and
CD161 NK-cell frequency decreased in the IFN-a2a but not the placebo
group. The frequencies of CD161 (Extended Data Fig. 8j), CD107a1 and
granzyme B1 NK cells at 12 w.p.i. were subsequently lower in the IFNa2a-treated macaques compared to placebo.
Taken together, these data show that despite initially increasing ISG
expression and conferring resistance to SIV infection, continued IFN-a2a
treatment resulted in an IFN-desensitized state, with decreased antiviral gene
expression, increased susceptibility to infection, increased cell-associated
virus load and greater CD4 T-cell depletion compared to placebo.
Thus, both IFN-I receptor blockade and IFN-a2a administration
ultimately resulted in decreased and delayed IFN-I responses, the biological outcomes of which reveal a pivotal role for IFN-I signalling in
acute retroviral exposure in primates that overshadows the potential
harm of increased inflammation. That a delay of as few as 3 days in
antiviral gene expression resulted in accelerated disease progression
suggests that SIV disease course is determined very early and depends
upon the precise timing of peak antiviral activity. The observation of
shortened time-to-death despite the eventual normalization of ISG
expression during chronic infection clearly shows that a resurgence
of late antiviral activity cannot compensate for compromised early virus
control. Indeed, administration of IFN-a in chronic HIV infection has
given inconsistent results for virus load and CD4 T-cell counts with no
effect on disease outcome7–9. An interesting parallel to our study was
recently described in mice with chronic lymphocytic choriomeningitis
virus infection where persistent IFN-I signalling exerts antiviral effects
but also leads to immune hyperactivation and suppression of antiviral
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T-cell responses14,15. Our findings differ from a previous study that reported
unchanged virus burden with IFN-a2a administration during chronic
SIV infection24 and a study of IFN-a2b or the IFN-aB/D chimaera in
rhesus macaques challenged intravenously with highly pathogenic SIV
DeltaB670 that showed no protection from infection but decreased peak
antigenaemia26. The initial protection from infection and decrease in
transmitted/founder variants observed in our study highlight the rectal
mucosa’s function as a barrier to SIV during transmission in the context of ISG induction. It is tempting to speculate that administration of
IFN-a2a before SIV challenge also facilitated NK-cell activation and
recruitment to the rectum and contributed to protection from infection27.
Given the relative IFN-I resistance of transmitted/founder viruses28,29 and
the induction of an IFN-desensitized state associated with the upregulation of the IFN-I pathway repressor FOXO3a (ref. 25), our findings
add a cautionary note to adjuvanted HIV vaccines or other prevention
approaches that induce ISGs at mucosal surfaces. Furthermore, while
the rectum contains many resident target CD4 T cells30 that antiviral
mediators can protect, sites with few resident target cells, such as the
female genital tract16, may depend on IFN-I signalling for CD4 T-cell
recruitment and virus propagation. Thus, inflammation might attenuate
transmission at the former site but exacerbate it at the latter3. In conclusion, disease progression in HIV infection emerges from the balance
between the beneficial antiviral effects of inflammation, its detrimental
systemic and immunologic effects, and its unique role of providing activated CD4 T-cell targets for HIV. Interfering with one part of this unstable
equilibrium has unpredictable consequences. Thus, while there is good
reason to use both pro- and anti-inflammatory therapeutic approaches
in the treatment and prevention of HIV infection, they should be embarked
upon with careful assessment of the virological and immunological consequences before widespread implementation.
Online Content Methods, along with any additional Extended Data display items
and Source Data, are available in the online version of the paper; references unique
to these sections appear only in the online paper.
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METHODS
Dose escalation study. We performed a dose escalation study in two rhesus macaques with chronic SIVMAC251 infection and different frequencies of CD4 T cells and
CCR51 CD4 and CD8 T cells to maximize the likelihood of detecting a response.
IFN-1ant was dosed three times a week based on dosing of recombinant IFN-a2a
(Roferon-A, Roche, Switzerland) for hepatitis C infection. We administered 50 mg of
IFN-1ant for one week, 200 mg for one week, 500 mg for one week and 800 mg for one
week. Based on a dose-dependent increase in CD4 T-cell frequency and decrease in
the frequencies of CCR51 CD4 and CCR51 and Ki671 CD8 T cells (Extended Data
Fig. 1a–d), and because of ease of administration, we decided on 1 mg of IFN-1ant.
Daily dosing was chosen as the effects appeared to be variable based on the time
since last dosing.
Macaques and experimental design. To examine the effects of blocking type I
IFN signalling, healthy, SIV-uninfected Mamu A012B082B172 adult Macaca mulatta
received 1 mg daily intramuscularly of the IFN-I receptor antagonist (IFN-1ant,
1 mg ml21, n 5 6; synthesized as previously described19) or 1 ml normal saline (n 5 9)
by intramuscular injection for 4 weeks (see Extended Data Fig. 1e). The macaques
were inoculated weekly, starting the first day of treatment, with 1 ml of SIVMAC251 via
rectal challenge (1 ml of a 1:25 dilution, stock 3 3 108 SIV RNA copies ml21), up to
three times until infection was confirmed (SIV pVL .250 copies ml21). Blood was
sampled several times per week, and lymph node and jejunal biopsies were performed before treatment and at the end of the 4-week period. All blood draws and
biopsies were performed before inoculation with SIVMAC251 and before any drug
administration on that day. The macaques were followed for up to 40 w.p.i.
To examine the effect of exogenous IFN-I treatment, six healthy, SIV-uninfected
Mamu A012B082B172 adult macaques received 6 mg kg21 pegylated IFN-a2a
(Pegasys, Genentech USA) intramuscularly weekly starting one week before the first
SIVMAC251 inoculation. Dose was based on prior efficacy studies in rhesus macaques24.
The macaques were challenged intrarectally weekly on the same day as, but before,
IFN-a2a administration, with the same high-dose SIVMAC251 inoculation as the IFN1ant and placebo macaques, until infection was confirmed. All blood draws and
biopsies were performed before inoculation with SIVMAC251 and before any drug
administration on that day. The macaques were followed for a total of 12 weeks
after infection and then euthanized per protocol. To examine the effect of exogenous IFN-I treatment in the absence of SIV infection, three healthy, SIV-uninfected
Mamu A012B082B172 adult macaques received 6 mg kg21 pegylated IFN-a2a
(Pegasys, Genentech USA) intramuscularly weekly for 3 weeks. Blood was sampled
twice weekly starting 1 week before IFN-a2a treatment through to 1 week after the
last dose. The lymph node, jejunum and rectum were biopsied before IFN-a2a
treatment, 1 week after the first dose and 1 week after the last dose.
All macaques were housed at Bioqual, Inc., and assigned randomly to treatment
or placebo arms. TRIMCyp, the fusion protein derived from TRIM5 and cyclophilin A, was present in 1 placebo macaque, 2 IFN-1ant macaques and 0 IFN-a2a
macaques. One TRIM5a SPRY deletion was present in 4 placebo macaques, 3 IFN1ant macaques and 1 IFN-a2a macaque (the macaque that required 5 challenges to
become systemically infected) and two TRIM5a SPRY deletions in 2 IFN-1ant
macaques. There was no significant difference in genotype distribution between
placebo and IFN-1ant macaques or between placebo and IFN-a2a macaques based
on Fisher’s test. Based on availability, the 6 IFN-1ant macaques and 9 placebo
macaques were male and ages 4 to 7 years, and the 6 IFN-a2a macaques were female
with ages 9 to 15 years. The Vaccine Research Center Animal Care and Use Committee approved all study protocols and procedures.
Samples. Blood was collected in EDTA tubes. Plasma was collected and PBMCs
were isolated by Ficoll density centrifugation. All of the jejunum and half the lymph
node biopsy tissues and half of every tissue collected at necropsy were placed in
RPMI with 10% fetal bovine serum (FBS) and transported on wet ice. The remaining tissues were placed in 4% paraformaldehyde and kept at room temperature
overnight before being transferred to 80% ethanol and stored at 4 uC. Tissues were
subsequently paraffin-embedded for in situ hybridization and immunohistochemistry. Intestinal samples were incubated with RPMI 1 collagenase D (1 mg ml21)
(Roche) 1 Penicillin-Streptomycin-Glutamine (Gibco) at 37 uC for 30 min and
then passed through a 70 mm filter. Lymph node samples were passed through a
70 mm filter to remove debris. Cells isolated from both peripheral blood and tissues
were either stained for flow cytometry or cryopreserved.
Flow cytometry. Cellular activation and cell cycle entry were assessed by flow
cytometry. PBMCs and cells from the jejunum and lymph nodes were stained with
Aqua LIVE/DEAD Fixable Dead Cell Stain and antibodies to the following: CD4
Qd605, CD8 Qd655 (Invitrogen); CD3 APC-Cy7, CD95 PE-Cy5, CD14 Pacific Blue,
CCR5 PE, CCR7 PE-Cy7, Ki67 FITC (BD Biosciences); CD28 ECD (Beckman Coulter);
and HLA-DR Alexa 700PE (BD Biosciences, in-house conjugate). Cells were permeabilized using a Cytofix/Cytoperm kit (BD Biosciences) for Ki67 detection and
fixed with 1% formaldehyde (Tousimis).

To assess antigen-specific responses and NK cell subsets, cryopreserved PBMCs
were stimulated for 6 h at 37 uC with SIV Gag/Env/Pol peptide pool (2 mg ml21)
in the presence of CD28 and CD49d (BD Biosciences) and brefeldin A (Sigma,
10 mg ml21). Cells were stained with Aqua LIVE/DEAD Fixable Dead Cell Stain
(Invitrogen) and antibodies to the following: CD3 APC-Cy7, CD14 Pacific Blue,
IFN-c Cy7PE, TNF APC, CD107a FITC (BD Biosciences); Granzyme B PE (Caltag);
CD4 Qd605, CD8 Qd655 (Invitrogen); CD16 Ax594, CD20 Ax700PE, CD56 Cy5PE,
Perforin Ax680 (in-house conjugates, BD Biosciences). Cells were permeabilized
using a Cytofix/Cytoperm kit (BD Biosciences) for intracellular cytokine detection
and fixed with 1% formaldehyde (Tousimis).
To evaluate cellular exhaustion, cryopreserved PBMCs were stimulated for 6 h
at 37 uC with SIV Gag/Env/Pol peptide pool (2 mg ml21) in the presence of brefeldin
A (10 mg ml21). Cells were stained with Aqua LIVE/DEAD Fixable Dead Cell Stain
(Invitrogen) and antibodies to the following: CD3 APC-Cy7, CD95 Cy5PE, IFN-c
FITC, TNF APC, Bcl-2 PE (BD Biosciences); CD28 ECD (Beckman Coulter); ICOS
Pacific Blue (Biolegend); CD4 Qd605, CD8 Qd655, Streptavidin Cy7PE (Invitrogen);
PD-1 biotinylated (R&D Systems). Cells were permeabilized using a Cytofix/Cytoperm
kit (BD Biosciences) for intracellular cytokine detection and fixed with 1% formaldehyde (Tousimis).
Transmitted/founder variant characterization. The number of transmitted/
founder variants were characterized blindly, as previously described28, and deposited in GenBank under accession numbers KJ201031 to KJ201503.
Determination of susceptibility of circulating SIV to IFN-a. Freshly isolated,
CD8-depleted PBMCs from naive rhesus macaque donors were stimulated for
3 days with 5 mg ml21 PHA and 100 U ml21 IL-2 in RPMI supplemented with 10%
FBS, 2 mM L-glutamine, 100 U ml21 penicillin and 100 mg ml21 streptomycin (RPMIComplete). Target cells were re-suspended at 106 cells ml21 in RPMI-Complete containing various concentrations of recombinant human IFN-a (PBL Interferon Source)
and incubated at 37 uC for 4 h. IFN-a-containing culture supernatants were collected
and stored at 37 uC. Target cells were split into duplicate cultures and spinoculated for
2 h at 800g with diluted, equivalent input amounts of SIV from plasma from 14 to
18 d.p.i. from IFN-a2a or placebo macaques. Cells were washed and re-suspended in
matched, stored IFN-a containing supernatants supplemented with 100 U ml21
IL-2. After incubation at 37 uC for 7 days, cell-free culture supernatants were collected and a SIV p27 antigen capture assay was used to detect the presence of viral
p27 antigen according to the manufacturer’s instructions (ABL).
Binding and neutralizing antibody assays. IFN-binding antibodies were assessed
as previously described31. To evaluate for neutralizing antibodies, A549 cells (American
Type Culture Collection, Manassas, VA) were seeded at 1 3 104 per well in RPMI with
2% FBS and 2 mM L-glutamine and incubated for 24 h. For the standard curve, IFNa2b (Hoffman La Roche, Nutley, NJ) was added to cells in twofold serial dilution from
5 IU ml21 to 0.04 IU ml21. For measurement of IFN-a2b-neutralizing antibodies
in plasma, IFN-a2b was added at a concentration of 0.5 IU ml21 along with 160-fold
diluted plasma. Control wells received medium only or 5 IU ml21 IFN-a2b and
13.1 mg ml21 of a control neutralizing antibody. After an additional 24 h, the media
was removed and replaced with RPMI 1640 containing 2% FBS, 2 mM L-glutamine
containing encephalomyocarditis virus (EMCV, American Type Culture Collection,
Manassas, VA) at a multiplicity of infection of 0.5. Cells were stained with crystal violet
at 52 h and assessed for cytopathic effect as measured by optical density at 570 nm.
Quantitative RT–PCR. RNA was extracted from PBMCs preserved in TRIzol (Life
Technologies) or from thawed cryopreserved PBMCs by RNAzol RT (Molecular
Research Center, Inc.) according to the manufacturers’ instructions. Purified RNA
was added directly to a one-step quantitative RT–PCR reaction containing iScript
RT-iTaq Taq enzyme mix (BioRad). MX1, OAS2 and b2 microglobulin were labelled
with a 59 FAM reporter and 39 BHQ1 quencher (Biosearch Technologies). We used
the following oligonucleotide sequences: MX1 F AGGAGTTGCCCTTCCCAGA,
MX1 R CCTCTGAAGCATCCGAAATC, MX1 P TGACCAGATGCCCGCTGGT
G; OAS2 F CAGTCCTGGTGAGTTTGCAGT, OAS2 R CAGCGAGGGTAAATCC
TTGA, OAS2 P GCACTGGCATCAACAGTGCCAGA.
MX1 and OAS2 forward and reverse primers were used at 500 nM, and probes at
200 nM. Samples were run on an Applied Biosystems Sequence Detection System
7900HT (ABI). Expression levels of MX1 and OAS2 were normalized to b2 microglobulin and calculated based on the DDCT method.
Transcriptome analysis. Total RNA was prepared as described above. Polyadenylated
transcripts were purified on oligo-dT magnetic beads, fragmented, reverse transcribed
using random hexamers and incorporated into barcoded cDNA libraries based on the
Illumina TruSeq platform. Libraries were validated by microelectrophoresis, quantified, pooled and clustered on Illumina TruSeq v2 flowcells. Clustered flowcells
were sequenced on an Illumina HiSeq 2000 in 100-base single-read reactions.
New rhesus macaque genome. RNA-Seq data were analysed by alignment to a provisional assembly (deposited under BioProject accession PRJNA214746) and annotation
of a new Indian Macaca mulatta genome (data provided by R.B.N., University of
Nebraska Medical Center and A. Zimin, University of Maryland). Comparison of
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RNA-seq data generated using the v.4 assembly demonstrated a greater absolute
number of mapping reads, higher proportion of mapped reads per sample than to
the hg19 RefSeq or RheMac2 assembly (Supplementary Fig. 1 and Supplementary
Information).
RNA-seq data analysis. RNA-seq data were submitted to The Gene Expression
Omnibus (GEO) repository at the National Center for Biotechnology Information
(NCBI). RNA-seq data were aligned to a provisional assembly of Indian Macaca
mulatta (MuSuRCA rhesus assembly v.4) using STAR version 2.3.0e32; parameters
were set using the annotation as a splice junction reference, un-annotated noncanonical splice junction mappings and non-unique mappings were removed from
downstream analysis. Transcripts were annotated using the provisional UNMC
annotation v4.12. Transcript assembly, abundance estimates and differential expression analysis were performed using Cufflinks v2.1.1 and Cuffdiff 33. Samples with ,49%
mapped reads or exhibiting considerable 39 or 59 bias were excluded from further
analysis. To reduce normalization bias due to varying read depths, samples were
analysed in two separate groups: group 1 comprised 166 samples and contained the
samples from PBMCs from the placebo1SIV, IFN-1ant1SIV, and pegylated IFNa2a-treated1SIV animals, and from samples for the analysis of PBMCs, LN CD4 T
cells and rectal biopsies of uninfected, IFN-a2a-treated animals; the average number of mapped reads was 12,188,890 (range: 3,237,374–87,371,564). Group 2 comprised the lymph node CD4 T cells from the three SIV-infected groups consisting
of 37 samples; the average mapped read count for this group was 4,898,448 (range:
1,173,455–19,310,483). Differentially expressed genes were defined by pair-wise comparison of each time point to the Day 0 baseline. We included genes that had any
acute time point (0 vs 7, 10, 21, 28) that was significantly differentially expressed by
a fixed discovery rate-corrected P value (q value) , 0.05. Differential gene lists were
uploaded to Ingenuity Pathway Analysis software (v1.0 Ingenuity Systems, http://
www.ingenuity.com/) and pathways with significant enrichment by Fisher’s exact
test and the Benjamini–Hochberg multiple testing correction were identified. Heat
maps and other visualization were generated using Partek Genomics Suite v6.6.
Gene-set enrichment analysis (GSEA). GSEA was performed using the desktop
module available from the Broad Institute (http://www.broadinstitute.org/gsea/).
FPKMs for samples from the IFN-a2a and placebo groups at 7 d.p.i. were pre-filtered
to remove transcripts with insufficient read coverage, and then were ranked using the
signal-to-noise statistic. The gene-set was comprised of genes determined to be
upregulated in unstimulated FOXO32/2 macrophages relative to macrophages from
control mice25. Significance was estimated using gene-set permutation.
SIV in situ hybridization, immunohistochemistry and quantitative image
analysis. SIV in situ hybridization was performed as previously described34. Immunohistochemistry for rabbit polyclonal anti-APOBEC3G (Prestige Antibodies
Powered by Atlas Antibodies HPA001812; Sigma-Aldrich), TRIM5a (Prestige Antibodies Powered by Atlas Antibodies HPA023422; Sigma-Aldrich) and MX2 (Prestige
Antibodies Powered by Atlas Antibodies HPA030235; Sigma-Aldrich) were performed using a biotin-free polymer approach (Rabbit Polink-2, Golden Bridge
International, Inc.) on 5 mm tissue sections mounted on glass slides, which were

dewaxed and rehydrated with double-distilled H2O. Antigen retrieval was performed by heating sections in 0.01% citraconic anhydride containing 0.05% Tween20 in a pressure cooker set at 122 uC for 30 s. Slides were rinsed in ddH2O, incubated
with blocking buffer (TBS containing 0.25% casein) and incubated with diluted
rabbit anti-APOBEC3G, rabbit anti-TRIM5a or rabbit anti-MX2 in blocking buffer
overnight at 4 uC. Tissue sections were rinsed in wash buffer (1 3 TBS containing
0.05% Tween-20) for 10 min followed by an endogenous peroxidase blocking step
using 1.5% (v/v) H2O2 in TBS (pH 7.4) for 10 min and placed in wash buffer. Slides
were incubated with rabbit Polink-2 HRP polymer-staining system (Golden Bridge
International, Inc.) according to manufacturer’s recommendations (20–30 min at
room temperature) then rinsed in wash buffer. Tissue sections were developed with
Impact 3,39-diaminobenzidine (Vector Laboratories), counterstained with haematoxylin and mounted in Permount (Fisher Scientific). All stained slides were scanned
at high magnification (3 200) using the ScanScope CS System (Aperio Technologies,
Inc.) yielding high-resolution digital scans of the entire tissue section. Regions of
interest of defined area (ROIs; 500 mm2) were saved on the digital image using the
Aperio rectangle tool (representing nearly the entire lymph node section) and highresolution images were extracted from the ROIs of each whole-tissue scan. The per
cent area of the lymph node (all anatomical compartments were included) that
stained for APOBEC3G, TRIM5a and MX2 were quantified under blind analysis
using Photoshop CS5 and Fovea tools.
Statistical methods. Based on our previous data of rhesus macaques with acute
SIV infection, the standard deviation for SIV RNA levels is 0.5 3 106 copies ml21.
Using this value, 6 macaques in the IFN-1ant or IFN-a2a group and 9 macaques in
the placebo group would give us 80% power to detect a 0.8 3 106 copies ml21
difference in SIV RNA levels between IFN-1ant or IFN-a2a and placebo groups.
Macaques were assigned to their respective groups randomly. Experiments, except
as noted above, were not performed blindly. All replicates are biological replicates.
Each experiment was performed once. Comparisons between groups at singular
time points were performed with the Mann–Whitney U test, comparisons within
groups with the Wilcoxon matched-pairs signed rank test, survival curve comparisons for per cent survival (IFN-1ant) and per cent uninfected (IFN-a2a) with the
log-rank (Mantel-Cox) test and correlations with Spearman coefficient, all using
GraphPad Prism v5.0d. Comparisons of AUCs were performed using linear
regression analysis adjusting for baseline values on JMP v10.
31.

32.
33.
34.

Vanderford, T. H. et al. Treatment of SIV-infected sooty mangabeys with a type-I
IFN agonist results in decreased virus replication without inducing
hyperimmune activation. Blood 119, 5750–5757 (2012).
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15–21 (2013).
Trapnell, C. et al. Differential analysis of gene regulation at transcript resolution
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Extended Data Figure 1 | Dose escalation study for IFN-1ant and
experimental schema. a–d, Effects of three times weekly IFN-1ant dosing on
the frequency of CD4 T cells (a), CCR51 CD4 T cells (b), CCR51 CD8 T cells
(c) and Ki671 CD8 T cells (d) in 2 rhesus macaques. Dose was 50 mg in week 1,
200 mg in week 2, 500 mg in week 3 and 800 mg in week 4. Vertical dotted lines
indicate the days a new dose was started. Black lines connect time points 4 days
after the first dose. Grey shading indicates treatment period. e, Six macaques
received 4 weeks of IFN-1ant intramuscularly starting at day 0 and were
challenged intrarectally with 1 ml of a 1:25 dilution of SIVMAC251 (stock

concentration 3 3 108 SIV RNA copies ml21) at day 0 and followed until
developing end-stage AIDS. Nine macaques were treated with 4 weeks of
placebo saline intramuscularly starting at day 0 and challenged intrarectally
with SIVMAC251 at day 0 and followed. Six macaques were injected weekly with
IFN-a2a starting 1 week before the first challenge and through 4 w.p.i.
Macaques required 2, 3 or 5 challenges to acquire systemic infection. Thus,
macaques received 6, 7 or 9 doses of IFN-a2a. Macaques were necropsied at
12 w.p.i. per protocol.
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Extended Data Figure 2 | Effects of IFN-1ant on IFN-stimulated genes and
virus burden. a, b, MX1 (a) and OAS2 (b) expression by qRT–PCR during
acute SIV infection in IFN-1ant (red, n 5 6) and placebo (blue, n 5 9)
macaques. P values were calculated by Mann–Whitney U test. c, ISGs in
PBMCs in IFN-1ant and placebo macaques. P values represent the comparison
between IFN-1ant (n 5 6) and placebo (n 5 9) macaque FPKMs at 7 d.p.i.
d, e, SAMHD1 (d) and APOBEC3G (e) expression in the lymph nodes in
IFN-1ant (n 5 6) and placebo (n 5 9) macaques. P values were calculated by

7 14 21 28 84
Days post-infection

Mann–Whitney U test. f, g, Plasma SIV RNA levels at 12 w.p.i. (f) or at peak
(g) stratified by the day that MX1 or OAS2 expression peaked in PBMCs in
IFN-1ant (n 5 6) and placebo (n 5 9) macaques. VL, viral load. P values were
calculated by Mann–Whitney U test. h, SIV gag levels in PBMCs stratified
by the day that MX1 or OAS2 expression peaked in PBMCs in IFN-1ant (n 5 6)
and placebo (n 5 6) macaques. P values were calculated by Mann–Whitney U
test. For all panels, IFN-1ant-treated macaques are represented in red,
placebo-treated macaques in blue.

©2014 Macmillan Publishers Limited. All rights reserved

RESEARCH LETTER

Extended Data Figure 3 | Effects of IFN-1ant on CD4 T cells and on
immune activation. a, b, CD4/CD8 T-cell ratio in peripheral blood (a) and
lymph node (LN) (b) in IFN-1ant (Ant, n 5 6) and placebo (Plac, n 5 9)
macaques. Shading indicates treatment period. Error bars indicate range. Red
vertical line indicates day 0 of systemic SIV infection. For all panels, horizontal
bars indicate median values, and P values at different time points within
treatment groups were calculated by Wilcoxon matched pairs signed rank test
and between groups by Mann–Whitney U test. c–f, T-cell activation in lymph

nodes (c–f) in CD4 (c, d) and CD8 (e, f) T cells as represented by the frequency
of Ki671 (c, e) or HLA-DR1 (d, f) cells in IFN-1ant (n 5 6) and placebo (n 5 9)
macaques. g, Frequency of circulating CD161 or CD561CD32CD142 NK
cells in IFN-1ant (n 5 6) and placebo (n 5 9) macaques. h, Frequency of
circulating CD161 NK cells in IFN-1ant (n 5 6) and placebo (n 5 9) macaques.
i, Frequency of circulating CD561 NK cells in IFN-1ant (n 5 6) and placebo
(n 5 9) macaques. For all panels, IFN-1ant-treated macaques are represented
in red, placebo-treated macaques in blue.
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Extended Data Figure 4 | IFN-1ant alters innate and adaptive immune
signalling. a, Selected pathways significantly affected by IFN-I blockade.
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compared to placebo (n 5 9) at 7 d.p.i. Upregulation compared to pre-infection
is represented by red, no change by white, downregulation by blue. P values
represent the comparison between IFN-1ant and placebo macaques at 7 d.p.i.
c, Selected genes in pattern recognition receptor signalling pathways.
Upregulation at 7 d.p.i. is represented by red, downregulation by green.
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Extended Data Figure 5 | Effects of IFN-1ant on T-cell function and
phenotype. a–e, SIV-specific responses in peripheral blood at 4 and .12 w.p.i.
in IFN-1ant (Ant, n 5 6) and placebo (Plac, n 5 6) macaques by frequency of
IFN-c1 (a), TNF1 (b), perforin1 (c), granzyme B1 (d) and CD1071 (e) CD8 T
cells. T-cell exhaustion in peripheral blood and lymph nodes (LN) at .16 w.p.i.

based on frequency of PD-11 CD4 (f) and CD8 (h) T cells and ICOS1 (g) CD8
T cells. For all panels, P values at different time points within treatment groups
were calculated by Wilcoxon matched pairs signed rank test and between
groups by Mann–Whitney U test. IFN-1ant-treated macaques are represented
in red, placebo-treated macaques in blue.
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Extended Data Figure 6 | IFN-a2a treatment transiently induces ISGs and
subsequently induces the IFN-repressor FOXO3a but does not induce
neutralizing anti-IFN antibodies. a–d, MX1 (a, c) and OAS2 (b, d) expression
during the duration of IFN-a2a treatment in the IFN-a2a group alone
(a, b) and during infection in the IFN-a2a (n 5 6) and placebo (n 5 9) groups
(c, d). P values were calculated by Wilcoxon matched pairs signed rank test.
e, Percentage of in vitro IFN antiviral activity inhibited by plasma from IFN-a2a
(n 5 6) and placebo (n 5 3) macaques. f, Expression of FOXO3a and

FOXO3a-bound genes in SIV-uninfected macaques (n 5 3) treated with 21 days of
IFN-a2a. Large circles indicate statistically significant (P,0.05) changes from
pre-IFN-a2a treatment calculated by Wilcoxon matched pairs signed rank test.
Small circles indicate no statistically significant change from pre-IFN-a2a
treatment. g, Expression of IFN-a-regulatory genes in IFN-a2a (n 5 6) and placebo
(n 5 9) macaques. P values represent the comparison between FPKMs of IFN-a2a
(n 5 6) and placebo (n 5 9) macaques at 7 d.p.i. h, Expression of FOXO3a-bound
genes in IFN-a2a (green, n 5 6) and placebo (blue, n 5 9) macaques at 7 d.p.i.
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Extended Data Figure 7 | Effects of IFN-a2a on IFN-stimulated and
antiviral genes. a, ISGs in PBMCs in IFN-a2a (n 5 6) and placebo (n 5 9)
macaques. Red indicates upregulation, yellow indicates no change and blue
indicates downregulation relative to pre-infection. b, Expression of ISGs in
macaques treated with IFN-a2a (n 5 6) or placebo (n 5 9). P values indicate
differentially expressed genes at 10 d.p.i. c–h, Expression of TRIM22

(c, d), MX2 (e, f) and IRF7 (g, h) in SIV-uninfected macaques (n 5 3) treated
with weekly IFN-a2a for 3 weeks in PBMCs (c, e, g) and lymph nodes and
rectum (d, f, h). Day 0 reflects baseline. Numbers indicate days since first IFNa2a administration. Error bars indicate range. P values were calculated by
Wilcoxon matched pairs signed rank test.
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Extended Data Figure 8 | Effects of IFN-a2a on SIV control. a, Number
of transmitted/founder (T/F) variants in placebo (n 5 9), IFN-1ant (n 5 6)
and IFN-a2a (n 5 6) macaques. P value was calculated by Mann–Whitney
U test. b, Antiviral protein production in lymph nodes (LN) by
immunohistochemistry at 4 w.p.i. in IFN-a2a (n 5 6) and placebo (n 5 6)
macaques. P value was calculated by Mann–Whitney U test. c, CD561 NK-cell
frequency on the day of challenge stratified by whether the macaque resisted
or was susceptible to systemic infection that day. Each IFN-a2a macaque
(n 5 6) is indicated by a different colour. Circles indicate that the macaque was
resistant to infection with the next challenge and triangles indicate that the
macaque was susceptible to infection with the next challenge. P value was
calculated by Mann–Whitney U test. d, Correlation between the number of

challenges required to achieve systemic infection and rectal CD161 NK-cell
frequency in each macaque (n 5 6) at 4 w.p.i. r indicates the Spearman’s rank
correlation coefficient. P value indicates the significance of the correlation.
e, Plasma SIV RNA levels in macaques treated with IFN-a2a (n 5 6) or placebo
(n 5 9) saline. Shading reflects treatment period. Red vertical line indicates day
0 of systemic SIV infection. f–i, Frequency of IFN-c1 (f), TNF1 (g), granzyme
B1 (h) and perforin1 (i) CD8 T cells at 4 and $12 w.p.i. in IFN-a2a (n 5 6) and
placebo (n 5 6) macaques. j, Frequency of circulating CD161CD562 NK cells
in IFN-a2a (n 5 6) and placebo (n 5 9) macaques. P values at different time
points within treatment groups were calculated by Wilcoxon matched pairs
signed rank test and between groups by Mann–Whitney U test.
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Extended Data Figure 9 | Effects of IFN-a2a on T-cell activation.
a–h, Frequency of peripheral blood (a–d) and lymph node (LN) (e–h) CD4
(a, c, e, g) and CD8 (b, d, f, h) memory T cells expressing HLA-DR (a, b, e, f) or
Ki67 (c, d, g, h) in IFN-a2a (IFN, n 5 6) and placebo (Plac, n 5 9) macaques.

Shading indicates treatment period. Error bars indicate range. a–d, Red vertical
line indicates day 0 of systemic SIV infection. P values represent the
comparison between groups of the AUC (0-4 w.p.i.). e–h, Horizontal bars
indicate median values. P values were calculated by Mann–Whitney U test.
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Extended Data Figure 10 | Effects of IFN-a2a on gene expression. a, Selected
pathways significantly affected by IFN-a2a treatment. P values were
calculated by Fisher’s exact test with the Benjamini–Hochberg multiple testing
correction. b, Expression of genes downstream of IL-6 signalling. Upregulation
relative to before IFN-a2a or placebo treatment and SIV infection is

represented by red, no change by white, downregulation by blue. P values
represent the comparison between IFN-a2a (n 5 6) and placebo (n 5 9)
macaques at 7 d.p.i. c, Selected genes in apoptosis signalling pathways.
Significant upregulation at 7 d.p.i. is represented by red, downregulation
by green.
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